drugset / Trial / NCT05667454
MAD Trial: Myopia Atropine Dose
Phase 3
Recruiting
550 enrolled
Erasmus Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.
Timeline
- Start
- 2022-12-19
- Primary completion
- 2029-03-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atropine | Other / unclassified | 0.05 % | Other |
| Comparator | Atropine | Other / unclassified | 0.5 % | Other |